Home › Researcher directory › Abdullah Esmail

Abdullah Esmail

Affiliation : Houston Methodist

2Publications (affiliation in the United States)
150Total publications
938Citations
18h-index

Research profile

Abdullah Esmail has 2 indexed publications (2022). Their work appears mainly in “Current Oncology” and “Frontiers in Pharmacology”. Their most cited article, “Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series” (2022), has been cited 25 times. Their work is co-authored with at least 11 researchers, including institutions in Jordan.

Is this you? Get your research seen

Create your free DzCademia profile and add your articles: they will show up more easily on Google and in AI assistants like ChatGPT, so more people can read and cite your work.

Create my free profile Add my publications

Research areas

Hepatocellular Carcinoma Treatment and Prognosis
Cancer Immunotherapy and Biomarkers
Colorectal Cancer Treatments and Studies
Cholangiocarcinoma and Gallbladder Cancer Studies
Cancer Genomics and Diagnostics

Publications (2)

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
2022 · Current Oncology · cited 25 times
Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
2022 · Frontiers in Pharmacology · cited 18 times

Publication venues

Current Oncology × 1
Frontiers in Pharmacology × 1

Collaborations

Partner institutions : Weill Cornell Medicine · Houston Methodist Research Institute · The University of Texas MD Anderson Cancer Center · University of Jordan · Buffalo State University

Co-authors’ countries : Jordan

Co-authors

Bibliographic data from OpenAlex (open database).